FIELD: chemistry.SUBSTANCE: invention relates to novel compounds of general formula (1) and pharmaceutically acceptable salts thereof, which exhibit inhibitory activity on phospholipase A2 enzyme and therefore have prostaglandin and/or leucotriene production suppressing action. In formula X is a halogen atom, cyano group, C1-C3 alkyl group, which can be substituted with halogen atoms, C1-C3 alkoxy group or hydroxy group, C2-C4 alkenyl group, C1-C3 alkoxy group or hydroxy group； Y is a hydrogen atom or C1-C3 alkyl group； Z is C1-C3 alkyl group； G is selected from formulae and , where in formulae (G2) and (G5) R4 is a hydrogen atom or C1-C6 alkyl group which can be substituted with halogen atoms； D is -NR10C(O)-, -C(O)NR10-, -S(O)2NR10- or -N(R11)-； R10 is a hydrogen atom； R11 is a hydrogen atom or C1-C3 alkyl group； A is a single bond, C1-C6 alkylene, which can be substituted with a phenyl group, or C2-C4 alkenylene； Q is a phenyl group or a 5-6-member aromatic heterocyclic group containing 1-3 heteroatoms selected from N, O, S, optionally substituted with a benzene ring； R5, R6 and R7 all or independently denote a hydrogen atom, a halogen atom, C1-C6 alkyl group which can be substituted with halogen atoms, C1-C6 alkoxy group which can be substituted with halogen atoms, phenyloxy group, phenyl group or a 5-6-member aromatic heterocyclic group containing 1-3 heteroatoms selected from N, O, where said phenyl group and 5-6-member aromatic heterocyclic group can be substituted with a C1-C3 alkyl group which can be substituted with halogen atoms or a C1-C3 alkoxy group. The invention also relates to specific compounds, a medicinal agent, a pharmaceutical composition, a phospholipase A2 enzyme activity inhibitor and a treatment method.EFFECT: improved method.21 cl, 56 tbl, 561 exИзобретение относится к новым соединениям общей формулы (1) и их фармацевтически приемлемым солям, которые проявляют ингибирующую активность в отношении фермента фосфолипазы А2 4 типа и таким о
